ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
20.214,79
-0,51%
S&P 500
5.843,37
-1,27%
Dow Jones
42.038,38
-1,40%
Euro vs US Dollar
1,02377
-0,57%
Bitcoin
94.923,82
2,71%
Pepperstone
Advertisement
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Elicio Therapeutics Inc (ELTX)

  7. Elicio Therapeutics Inc (ELTX) News

ELTX

Elicio Therapeutics (ELTX)

Elicio Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ELTX
DatumZeitQuelleÜberschriftSymbolFirma
07/01/202522h30Edgar (US Regulatory)Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:ELTXElicio Therapeutics Inc
18/12/202422h51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
12/12/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
12/12/202413h00GlobeNewswire Inc.Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024NASDAQ:ELTXElicio Therapeutics Inc
03/12/202413h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
03/12/202413h00GlobeNewswire Inc.Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study EnrollmentNASDAQ:ELTXElicio Therapeutics Inc
25/11/202413h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
25/11/202413h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
22/11/202414h06Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ELTXElicio Therapeutics Inc
21/11/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
21/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ELTXElicio Therapeutics Inc
13/11/202422h21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ELTXElicio Therapeutics Inc
13/11/202422h05GlobeNewswire Inc.Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
07/11/202422h27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
07/11/202422h05GlobeNewswire Inc.Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual MeetingNASDAQ:ELTXElicio Therapeutics Inc
07/11/202415h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
31/10/202413h30GlobeNewswire Inc.Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation SummitNASDAQ:ELTXElicio Therapeutics Inc
17/10/202414h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ELTXElicio Therapeutics Inc
16/10/202414h30GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
02/10/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
02/10/202422h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
02/10/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ELTXElicio Therapeutics Inc
27/09/202422h42Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ELTXElicio Therapeutics Inc
27/09/202422h41Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ELTXElicio Therapeutics Inc
17/09/202422h05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ELTXElicio Therapeutics Inc
17/09/202414h31GlobeNewswire Inc.Elicio Therapeutics Reports Inducement GrantsNASDAQ:ELTXElicio Therapeutics Inc
13/09/202414h30GlobeNewswire Inc.Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile VaccinesNASDAQ:ELTXElicio Therapeutics Inc
28/08/202414h00GlobeNewswire Inc.Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ELTXElicio Therapeutics Inc
13/08/202422h30GlobeNewswire Inc.Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:ELTXElicio Therapeutics Inc
12/08/202422h05GlobeNewswire Inc.Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible NoteNASDAQ:ELTXElicio Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ELTX

Kürzlich von Ihnen besucht

FX
EURGBP
Euro vs Sterling
AMEX
XLF
Financial Select Sector
CCOM
US30
US 30
DBI
MDAX
MDAX
COIN
SOLUSD
Solana
CCOM
US500
US 500
NYSE
KO
Coca Cola
COIN
AVAXUSD
Avalanche
TG
TUI1
Tui
NASDAQ
TSLA
Tesla
TG
D7G
Nel ASA
USOTC
DTEGY
Deutsche Telekom (QX)
TG
DBK
Deutsche Bank
NYSE
XOM
Exxon Mobil
NASDAQ
NVDA
NVIDIA
NASDAQ
GOOGL
Alphabet
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten